PET Scans Identify Brain Inflammation in Veterans with Gulf War Illness

Article

Neuroinflammation discovered in regions of the brain that control higher-order functions.

Veterans diagnosed with Gulf War Illness (GWI) have significantly higher elevations of brain inflammation than other individuals – a finding from a new study that could support treating neuroinflammation as a potential therapeutic target.

These soldiers experience neuroinflammation in areas of the brain that are responsible for executive functions, including memory, concentration, and reasoning. This symptom was similar to what is seen in patients with fibromyalgia, according to researchers from Massachusetts General Hospital’s Athinoula A. Martinos Center for Biomedical Imaging led by Marco Loggia, Ph.D., associate professor of radiology at Harvard Medical School.

The study, published in Brain, Behavior, and Immunity, is the first to provide direct evidence of higher levels of a neuroinflammatory marker in Gulf War veterans compared to other individuals.

GWI affects approximately 30 percent of soldiers who served during the 1991 Gulf War. It prompts fatigue, chronic pain, and cognitive problems, such as memory loss, but the root cause remains unknown. Some investigator have hypothesized the condition could result from exposure to nerve gas and the medication that counteracts the neurotoxin, pesticide exposure, sleep deprivation, stress associated with extreme temperature changes, and physical exertion during deployment.

To determine whether veterans with GWI experience neuroinflammation like fibromyalgia patients, Loggia’s team used PET imaging to scan the brains of 23 veterans, 15 who had GWI and 25 healthy civilians. The scans used the radioligand [11C]PBR28 to track and measure the levels of translocator protein, a molecule that increases in amount in the glial cells that surround and insulate neurons during the neuroinflammatory response. The areas that had the most inflammation were the precuneus, prefrontal cortex, and primary motor and somato-sensory areas.

The imaging revealed veterans with GWI had more extensive neuroinflammation than their healthy counterparts. Further research with a larger study population is needed to validate the results and determine whether glial modulation could be an effective therapy for these soldiers.

These findings also add to the existing body of knowledge on the implications of neuroinflammation from Loggia’s lab. Prior research indicates neuroinflammation also plays a role in many other conditions, including chronic pain, depression, anxiety, and autism. In addition, it could be integral to amyotrophic lateral sclerosis (ALS), multiple sclerosis, Huntington’s disease and migraine.

The hope, Loggia said, is that the findings with veterans with GWI “could help motivate a more aggressive evaluation of neuroinflammation as a potential therapeutic target.”

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.